Desfinanciación de diacereinaimpacto económico en la comunidad autónoma del País Vasco

  1. Elizondo López de Landache, Isabel 1
  2. Braceras Izaguirre, Leire 1
  3. Gardeazabal Romillo, María José 1
  4. Acevedo Heranz, Paloma 1
  1. 1 Servicio de Prestaciones Farmacéuticas. Dirección de Farmacia. Departamento de Sanidad y Consumo(Salud). Gobierno Vasco
Journal:
Gaceta médica de Bilbao: Revista oficial de la Academia de Ciencias Médicas de Bilbao. Información para profesionales sanitarios

ISSN: 0304-4858,  2173-2302

Year of publication: 2013

Volume: 110

Issue: 3

Type: Article

DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Gaceta médica de Bilbao: Revista oficial de la Academia de Ciencias Médicas de Bilbao. Información para profesionales sanitarios

Abstract

Objective: To analyze the economic impact if diacerein had been excluded among the drugs funded by the Spanish National Health Service. Methods: We performed a descriptive study of the use of medication for osteoarthritis in the Basque Country. Results: A total of 140,665 packs of drugs were used for the treatment of osteoarthritis. The most commonly used active ingredient was chondroitin sulfate (46.43%), which represented an expenditure of somewhat more than 1.2 M €, followed by glucosamine and diacerein. Conclusions: The policy of excluding drugs from the publicly-funded health system does not lead to savings, since multiple factors influence drug prescription.

Data source: Dialnet